Hikma Pharmaceuticals USA Announces $1 Billion Investment to Expand US Manufacturing and R&D by 2030

Introduction

On June 28, 2025, Hikma Pharmaceuticals USA declared a significant investment of $1 billion by 2030 to enhance its US-based manufacturing and research and development (R&D) capabilities. This initiative, titled America Leans on Hikma: Quality Medicines Manufactured in the USA, builds upon over 34 years of service to US patients and healthcare providers. The expansion aims to support the Sustainable Development Goals (SDGs) by promoting good health and well-being (SDG 3), decent work and economic growth (SDG 8), and industry, innovation, and infrastructure (SDG 9).

Background and Current Capabilities

• Hikma has operated in the United States since 1991.
• Over the past 15 years, the company has invested more than $4 billion to develop and expand US-based R&D and manufacturing.
• Current annual domestic production capacity exceeds 12 billion finished doses of essential medicines.
• Hikma provides a broad range of generic medicines at lower costs compared to branded products, enhancing access to affordable healthcare (SDG 3).
• The company maintains an excellent record of US FDA quality inspections and actively collaborates to resolve critical drug shortages.

Expansion Details and Locations

The new investment phase will expand Hikma’s manufacturing and R&D footprint across multiple US sites, including:

1. Columbus, Ohio
2. Cleveland, Ohio
3. Cherry Hill, New Jersey
4. Dayton, New Jersey

This expansion will strengthen a portfolio of over 800 medicines and increase the capacity to produce high-quality, affordable medicines for American hospitals, healthcare providers, and patients, aligning with SDG 3 and SDG 9.

Statements from Leadership and Officials

• Dr. Hafrun Fridriksdottir, President, Hikma Rx: Emphasized the commitment of Hikma and its 2,300 US employees to support healthier communities nationwide by ensuring a reliable supply of domestically produced quality medicines.
• Dr. Bill Larkins, President, Hikma Injectables: Highlighted Hikma’s position as a top three US supplier of sterile injectable medicines by volume, with over 180 injectable products and a growing pipeline. The investment will enhance sterile injectables production capacity.
• Rep. Buddy Carter (GA-01): Recognized the importance of onshoring generic medicine production to strengthen national security and public health, applauding Hikma’s efforts to deliver affordable and accessible medicines.
• Rep. Mike Carey (OH-15): Expressed support for Hikma’s investment in American workers and the creation of jobs in central Ohio, emphasizing the importance of increasing access to affordable, high-quality medicines.

Alignment with Sustainable Development Goals (SDGs)

• SDG 3 – Good Health and Well-being: By expanding production of essential medicines, Hikma contributes to ensuring healthy lives and promoting well-being for all ages.
• SDG 8 – Decent Work and Economic Growth: The investment supports job creation and economic development in US communities, particularly in Ohio and New Jersey.
• SDG 9 – Industry, Innovation, and Infrastructure: Enhancing manufacturing and R&D infrastructure fosters innovation and strengthens the pharmaceutical industry’s capacity to meet healthcare demands.
• SDG 12 – Responsible Consumption and Production: Hikma’s focus on quality and reliable supply chains supports sustainable production practices.

Commitment to Affordable and Accessible Healthcare

Hikma reaffirms its mission to provide affordable and accessible healthcare solutions by ensuring a steady supply of essential medications for all Americans. This investment reflects the company’s dedication to supporting public health and strengthening the US pharmaceutical manufacturing base.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC (LSE: HIK) is a global healthcare company headquartered in the UK, with a significant presence across North America, the Middle East and North Africa (MENA), and Europe. For over 45 years, Hikma has focused on creating high-quality medicines and making them accessible worldwide. The company employs approximately 9,500 colleagues globally and offers a broad range of branded and generic medicines. Hikma is also a leading licensing partner and actively invests in innovative health technologies through its venture capital arm.

For more information, visit: www.hikma.com

Contact Information

1. Sustainable Development Goals (SDGs) Addressed or Connected

1. SDG 3: Good Health and Well-being
   • The article focuses on expanding the production of high-quality, affordable medicines in the USA, which directly supports ensuring healthy lives and promoting well-being for all ages.
2. SDG 8: Decent Work and Economic Growth
   • Investment in manufacturing and R&D facilities creates jobs and supports economic growth in local communities, as highlighted by the creation of jobs in central Ohio.
3. SDG 9: Industry, Innovation, and Infrastructure
   • The expansion of pharmaceutical manufacturing and R&D capabilities demonstrates investment in resilient infrastructure, innovation, and sustainable industrialization.
4. SDG 12: Responsible Consumption and Production
   • Producing affordable generic medicines domestically can contribute to more sustainable production and consumption patterns in the pharmaceutical sector.

2. Specific Targets Under the Identified SDGs

1. SDG 3: Good Health and Well-being
   • Target 3.8: Achieve universal health coverage, including access to quality essential medicines and vaccines.
   • Target 3.b: Support the research and development of vaccines and medicines for communicable and non-communicable diseases.
2. SDG 8: Decent Work and Economic Growth
   • Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading, and innovation.
   • Target 8.5: Achieve full and productive employment and decent work for all women and men.
3. SDG 9: Industry, Innovation, and Infrastructure
   • Target 9.2: Promote inclusive and sustainable industrialization and, by 2030, significantly raise industry’s share of employment and gross domestic product.
   • Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors.
4. SDG 12: Responsible Consumption and Production
   • Target 12.4: Achieve the environmentally sound management of chemicals and all wastes throughout their life cycle.
   • Target 12.5: Substantially reduce waste generation through prevention, reduction, recycling, and reuse.

3. Indicators Mentioned or Implied to Measure Progress

1. SDG 3 Indicators
   • Proportion of population with access to affordable essential medicines (implied by the focus on affordable generic medicines).
   • Number of essential medicines produced domestically (implied by production capacity of over 12 billion doses annually).
2. SDG 8 Indicators
   • Number of jobs created in pharmaceutical manufacturing and R&D (implied by the mention of 2,300 US employees and job creation in Ohio).
   • Growth rate of pharmaceutical sector employment and productivity (implied by investment and expansion).
3. SDG 9 Indicators
   • Investment in research and development (explicit $1 billion investment by 2030).
   • Number of new or improved pharmaceutical products developed (implied by expanding portfolio and pipeline of medicines).
4. SDG 12 Indicators
   • Volume of generic medicines produced as a share of total pharmaceutical production (implied by focus on generics to reduce costs and waste).

4. Table of SDGs, Targets, and Indicators

Source: prnewswire.com